CSB 2.012 Note CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). (1) Section 961.14 (4) (wj), Stats., is created to read:

CSB 2.012 Note Section 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT”;

CSB 2.012 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.

CSB 2.012 Note CSB 2.35 Addition of lisdexamfetamine to schedule II. (1) Section 961.16 (5) (e), Stats., is created to read:

CSB 2.012 Note Section 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM.”

CSB 2.012 History History: CR 10-112: cr. Register April 2011 No. 664, eff. 5-1-11.

CSB 2.012 Note CSB 2.36 Addition of tramadol to schedule IV. Section 961.20 (4) (e), Stats., is created to read:

CSB 2.012 Note Section 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers.

CSB 2.012 History History: cr. Affirmative action order under s. 968.11 (4), Stats., Register August 2014 No. 704, eff. 9-1-14; CR 15-008: cr. Register October 2015 No. 718, eff. 11-1-15.

CSB 2.012 Note CSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.

CSB 2.012 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-007: cr. Register October 2015 No. 718, eff. 11-1-15.

CSB 2.012 Note CSB 2.38 Addition of suvorexant to schedule IV. Section 961.20 (2) (mr), Stats., is created to read:

CSB 2.012 Note Section 961.20 (2) (mr) Suvorexant.

CSB 2.012 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-009: cr. Register October 2015 No. 718, eff. 11-1-15.

CSB 2.012 Note CSB 2.39 Exclusion of naloxegol. Section 961.16 (2) (a) (intro.), Stats., is amended to read:

CSB 2.012 Note 961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:

CSB 2.012 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2015 No. 711B, eff. 4-1-15; CR 15-068: cr. Register August 2016 No. 728, eff. 9-1-16.

CSB 2.012 Note CSB 2.40 Exclusion of [123I]ioflupane. Section 961.16 (2) (b), Stats., is amended to read:

CSB 2.012 Note (b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:

CSB 2.012 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2015 No. 718A3, eff. 10-19-15; correction made under s. 35.17, Stats., Register October 2015 No. 718; CR 16-060: cr. Register May 2017 No. 737, eff. 6-1-17.

CSB 2.012 Note CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections 961.14 (2) (eu) and (ey) are created to read:

CSB 2.012 Note 961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)

CSB 2.012 Note (ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)

CSB 2.012 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2016 No. 728, eff. 7-18-16; CR 16-081: cr. Register July 2017 No. 739, eff. 8-1-17.

CSB 2.012 Note CSB 2.42 Scheduling of furanyl fentanyl. Section 961.14 (2) (ne) is created to read:

CSB 2.012 Note 961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).

CSB 2.012 History History: EmR1626: emerg. cr., eff. 9-1-16; CR 16-059: cr. Register May 2017 No. 737, eff. 6-1-17.

CSB 2.012 Note CSB 2.43 Addition of brivaracetam to schedule V. Section 961.22 (6), Stats., is created to read:

CSB 2.012 Note 961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.